FGFR1 and lymphoid neoplasm: Among them, pemigatinib, a reversible ATP-competitive FGFR inhibitor, has been recently approved as a novel drug for treatment of myeloid/lymphoid neoplasms with FGFR1 rearrangement in the US and Japan.